IOP lowering

Tracking treatment adherence in newly diagnosed open-angle glaucoma
Tracking treatment adherence in newly diagnosed open-angle glaucomaAn analysis of U.S. claims data reveals a substantial proportion of patients (17%) remained untreated 4 years after their initial diagnosis of open-angle glaucoma.
European study with microstent demonstrates lowered IOP, use of fewer drugsPatients with cataract surgery and microstent implantation had a lowered IOP and a reduced number of medications used at 3 years postoperatively
Novel ocular hypotensive drug meets endpointsNetarsudil ophthalmic solution 0.02% met its primary and secondary efficacy endpoints in a third phase III trial investigating its non-inferiority to timolol maleate 0.05% for IOP lowering.
Addressing ocular surface toxicity in glaucoma patientsDry eye is common in patients with glaucoma and often presumed to be related to the preservative in IOP-lowering medications. Considering alternate causes should also be weighed, in addition to a variety of management techniques.
Novel dual agonist leads to notable IOP loweringThe drug ONO-9054 led to a greater reduction in IOP and a longer duration of reduction in a small clinical trial compared with latanoprost.
Laser therapy addresses bilateral glaucoma in single treatmentLaser therapy that approaches bilateral glaucoma in a single treatment provides greater efficacy for the practice and more convenience for patients.
Rocket 2 meets safety endpoints for netarsudilNetarsudil ophthalmic solution 0.02% q.d. maintained consistent IOP-lowering efficacy through 12 months for the Rocket 2 trial.
Viscoelastic injection may improve microstent efficacyPatients receiving a sodium hyaluronate ophthalmic viscoelastic device injection showed a trend toward greater reduction in IOP than patients who received a microstent alone.
Gel stent for glaucoma patients finds 40% reduction in IOPImplantation of a gel stent for glaucoma studied in Europe led to a 40% reduction in IOP.
Taking a closer look at low-tension glaucoma risk factors, treatment guidelinesA reasonable goal for patients with low-tension glaucoma patients is an IOP that’s 30% below the untreated baseline. However, some patients will continue to progress and may require single-digit target IOP goals.